A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.
Alessandro D. Santin(Yale University), Michael J. Birrer(University of Arkansas Medical Center), Samir N. Khleif(Georgetown University), Heather A. Lankes(Nationwide Children's Hospital), Roisin E. O’Cearbhaill(Memorial Sloan Kettering Cancer Center), Warner K. Huh(University of Alabama at Birmingham), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Wei Deng(Gynecologic Oncology Group), Elena Ratner(Yale University)
Cited by 11
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846